Battle Over Patents And Drug Pricing Engulfs FDA And USPTO
Executive Summary
President Biden and Congress are pressuring the agencies to change patent policies so brand manufacturers cannot delay generic and biosimilar competition to keep monopoly prices. Timeline shows how they have responded to these demands.
You may also be interested in...
Pharma Industry Wants USPTO To Hit Brakes On Changes To Patent Continuation Practice
AbbVie, Amgen, Genentech, Bristol-Myers Squibb and others call on the patent office to retain the current system for continuation applications in comments on the USPTO and FDA’s proposed initiatives.
What Will USPTO-FDA Collaboration Look Like? Stakeholders To Weigh In On Proposed Initiatives
Agencies are holding public ‘listening session’ to get input on method of use patents and ‘skinny labeling,’ REMS patenting, PTAB proceedings and other topics.
Patent Process Reforms Proposed By US PTO Could Be ‘Quite Burdensome’ For Applicants
Patent office requests comments on its proposed initiatives, with continuation patents appearing a particular target. PTO asks if filing a terminal disclaimer for patents that are a variation of each other should be an admission they are obvious.